|
Name: Meperidine intermediate-B
Type: Opioid
AKA: Meperidine precursor, normeperidine
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
|
|
IV. History
Meperidine, a synthetic opioid, was first synthesized in the 1930s. It was developed for its analgesic properties and was used as a pain management medication. Meperidine's use has decreased over time due to the development of newer opioids with better safety profiles. Its history reflects early advancements in opioid analgesia and its evolving role in pain management.
|
|
V. Legal Information
Meperidine Intermediate-B is a precursor in the synthesis of meperidine, a controlled opioid. Its regulation is part of broader efforts to control opioid production and misuse. In the U.S., it is managed under precursor chemical laws. Internationally, its control reflects global efforts to combat opioid abuse and trafficking. [Source: UNODC].
US Federal Schedule - II
Schedule II drugs, substances, or chemicals are defined as drugs with a high potential for abuse, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous. Some examples of Schedule II drugs are: combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Meperidine Intermediate-B is a precursor to meperidine, an opioid analgesic. It has similar effects, including sedation and pain relief. It causes constricted pupils, reduced heart rate, and respiratory depression. Short-term effects include effective pain management, while long-term use may lead to addiction and respiratory complications. Overdose risks involve severe respiratory depression. Safe use requires medical oversight. Recent research highlights its role in opioid synthesis and associated risks.  |
|
VII. Psychological Effects
Meperidine intermediate-B, a precursor in opioid synthesis, has limited direct psychological effects. It may affect opioid receptors indirectly, but its psychological impacts are not well-documented. Research focuses on its role in opioid synthesis rather than significant psychological effects.
 |
|
VIII. Culture
Meperidine Intermediate-B is a precursor in the synthesis of meperidine, an opioid analgesic, classifying it as a downer. Short-term use in its final form provides pain relief, while long-term use can lead to dependence and tolerance. Overdose risks are high, causing respiratory depression and potentially fatal outcomes. Safe dosages of meperidine are medically prescribed, typically under 150 mg per dose. Recent research highlights the need for cautious prescribing due to addiction risks. Physical effects include drowsiness, constricted pupils, and respiratory depression.
 |